Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Becnel MR"'
Autor:
Fang P; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: pfang@mdanderson.org., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Saini N; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kaufman G; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Amini B; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lin P; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 May 01; Vol. 119 (1), pp. 193-199. Date of Electronic Publication: 2023 Dec 08.
Autor:
Dang M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hao D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lutter-Berka Z; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Berrios Nolasco DA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bansal H; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moreno Rueda LY; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Symer DE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green MR; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rojas Hernandez CM; Department of Internal Medicine, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kroll M; Department of Internal Medicine, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Afshar-Khargan V; Department of Internal Medicine, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ndacayisaba LJ; University of Southern California, Los Angeles, CA, USA., Kuhn P; University of Southern California, Los Angeles, CA, USA., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA. Electronic address: lwang22@mdanderson.org., Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: eemanasanch@mdanderson.org.
Publikováno v:
Cancer cell [Cancer Cell] 2023 Jun 12; Vol. 41 (6), pp. 1032-1047.e4.
Autor:
Shank BR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX., Primeaux B; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX., Yeung EK; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX., Horowitz SB; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee IY; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX., Roccograndi L; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Kaufman GP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: sthomas@mdanderson.org.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Apr; Vol. 23 (4), pp. 279-290. Date of Electronic Publication: 2022 Dec 10.
Autor:
Mohan M; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Becnel MR; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Shah UA; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Dong H; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Gundarlapalli S; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Peterson T; Janssen Pharmaceuticals, Beerse, Belgium., Orozco JS; Janssen Pharmaceuticals, Beerse, Belgium., Horowitz S; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Chhabra S; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Dhakal B; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Thanendrarajan S; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Radhakrishnan SV; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Al Hadidi S; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Tan C; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Mailankody S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Korde N; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Lesokhin AM; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Thomas SK; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Patel KK; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Manasanch EE; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Weber DM; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Szabo A; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Kaufman GP; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Lee HC; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Zangari M; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., van Rhee F; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Usmani SZ; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., D'Souza A; Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA., Orlowski RZ; The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA., Schinke C; Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Publikováno v:
American journal of hematology [Am J Hematol] 2022 Jul; Vol. 97 (7), pp. E276-E280. Date of Electronic Publication: 2022 May 02.
Autor:
Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
Publikováno v:
Therapeutic advances in hematology [Ther Adv Hematol] 2020 Dec 14; Vol. 11, pp. 2040620720979813. Date of Electronic Publication: 2020 Dec 14 (Print Publication: 2020).
Autor:
Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Samaniego F; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davis RE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., You MJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hagemeister FB; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fanale MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Seattle Genetics Inc., Bothell, WA, USA., Fayad LE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin JR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oki Y; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Forbes SG; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng L; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fowler NH; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
British journal of haematology [Br J Haematol] 2019 Jun; Vol. 185 (5), pp. 874-882. Date of Electronic Publication: 2019 Mar 28.
Autor:
Hill BT; Cleveland Clinic, Cleveland, OH, USA., Nastoupil L; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Winter AM; Cleveland Clinic, Cleveland, OH, USA., Becnel MR; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cerhan JR; Mayo Clinic, Rochester, MN, USA., Habermann TM; Mayo Clinic, Rochester, MN, USA., Link BK; University of Iowa Hospitals and Clinics, Iowa City, IA, USA., Maurer MJ; Mayo Clinic, Rochester, MN, USA., Fakhri B; Washington University School of Medicine, Saint Louis, MO, USA., Reddy P; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA., Smith SD; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA., Mukhija D; Cleveland Clinic, Cleveland, OH, USA., Jagadeesh D; Cleveland Clinic, Cleveland, OH, USA., Desai A; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA., Alderuccio JP; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA., Lossos IS; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA., Mehra P; University of Virginia, Charlottesville, VA, USA., Portell CA; University of Virginia, Charlottesville, VA, USA., Goldman ML; Emory University, Atlanta, GA, USA., Calzada O; Emory University, Atlanta, GA, USA., Cohen JB; Emory University, Atlanta, GA, USA., Hussain MJ; Levine Cancer Institute, Charlotte, NC, USA., Ghosh N; Levine Cancer Institute, Charlotte, NC, USA., Caimi P; University Hospitals of Cleveland, Cleveland, OH, USA., Tiutan T; Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY, USA., Martin P; Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY, USA., Kodali A; Tufts University School of Medicine and Cancer Center, Boston, MA, USA., Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Kahl BS; Washington University School of Medicine, Saint Louis, MO, USA.
Publikováno v:
British journal of haematology [Br J Haematol] 2019 Feb; Vol. 184 (4), pp. 524-535. Date of Electronic Publication: 2018 Dec 21.
Autor:
Becnel MR; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA. MRBecnel@mdanderson.org., Nastoupil LJ; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
Publikováno v:
Current treatment options in oncology [Curr Treat Options Oncol] 2018 May 24; Vol. 19 (7), pp. 32. Date of Electronic Publication: 2018 May 24.